38 results about "ANTI-DEMENTIA DRUGS" patented technology

The invention provides sustained release formulations of basic drugs, stereoisomers of basic drugs, pharmaceutically acceptable salts of basic drugs, and pharmaceutically acceptable salts of stereoisomers of basic drugs. The basic drugs may be anti-dementia drugs, such as cholinesterase inhibitors or memantine. In one embodiment, the cholinesterase inhibitor is donepezil.

Disclosed is a percutaneous absorption preparation which enables the stable administration of an antidementia drug over a long period of time. More particularly, the percutaneous absorption preparation of the antidementia drug which is used as a plaster on skin comprises at least an adherent layer, an intermediate membrane, and a drug reservoir layer sequentially from the side which is plastered on skin, wherein the drug reservoir layer comprises at least an antidementia drug, an aminated polymer, a polyhydric alcohol, and one or more carboxylic acid esters, the intermediate membrane enables the controlled permeation of the antidementia drug into the side of skin, the adherent layer enables the plastering of the percutaneous absorption preparation on skin, and is permeable to the antidementia drug.

An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist.

An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on the dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of the anti-dementia drugs, for which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide: a composition, for which the frequency of administration and the amount taken are reduced, and hence compliance can be improved; and a method of manufacturing such a composition. According to the present invention, there are provided a composition containing at least two kinds of the anti-dementia drugs; such a composition containing at least one sustained release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist.

The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.

The present invention relates to the field of pharmaceutical chemistry and therapeutics, and particularly relates to an optically active butylphthalide open-ring derivative as shown in the general formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, preparation methods thereof, pharmaceutical compositions containing the compounds, and medical application thereof, especially application in medicines for prevention and treatment of cardiovascular and cerebrovascular and improvement of heart and brain circulatory disturbance, antiplatelet aggregation medicines, antithrombotic medicines, anti-ischemic medicines, anti-dementia medicines, anti-atherosclerotic medicines, and medicines for anti-diabetes and complications thereof. Pharmacological experimental results show that the compounds have good anti-platelet aggregation activity, anti-thrombotic activity, anti-ischemic activity and neuroprotective effects, and are clinically useful for the preparation of medicines for preventing or treating diseases associated with platelet aggregation.

The present invention relates to a medicine composite with imidazoline acceptor excitation activity, and preparation method of said medicine composite and its application. Said medicine composite contains the extracts of Chinese medicinal materials of prunella spike, gentian root, leonurus, white peony root and licorice. Said medicine composite can be used for preparing the medicines for curing heart failure, arrhythmia, dementia for curing heart failure, arrhythmia, dementia and reducing blood pressure, etc.

An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist.

The invention relates to a building method and application of an STCH (stress and chaperone) gene knock-out animal model. The model can function as an animal model for the research of occurrence of depression and/or dementia. The model is prepared by using a gene knock-out technique, animal behavior detections show that a mouse suffers depression-like symptoms (forced swimming test and tail suspension test) and memory dysfunction (water maze test) while it grows older and has depression and dementia-like symptoms, and the model is applicable to screening anti-depression and anti-dementia drugs.

The present invention relates to a percutaneous absorption preparation that is lower skin irritation and enables efficient transdermal administration of an anti-dementia drug. More specifically, the present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, a polymer compound having an amino group, a polyvalent carboxylate ester, a fatty acid alkyl ester, a styrenic polymer compound, and a tackifier resin.

The invention relates to a preparation method and pharmaceutical applications of glycosyl modified butylphthalide ring-opened derivatives, and belongs to the fields of carbohydrate chemistry, medicinal chemistry and drug therapeutics. The invention provides obtained butylphthalide ring-opened derivatives, as well as pharmaceutical compositions containing the compounds and the pharmaceutical applications thereof, especially applications in drugs for prevention and treatment of cardio-cerebral ischemia disease, antiplatelet aggregation drugs, antithrombotic drugs, anti-cerebral ischemia drugs, anti-dementia drugs and anti-arteriosclerosis drugs. The results of pharmacological experiments show that the compounds have good antiplatelet aggregation activity and can be used in preparation of drugs for preventing or treating diseases related to platelet aggregation.

The invention provides an anti-falling medicine cup for dementia patients, which belongs to the field of psychiatric medical instruments. It solves the problem that the existing Alzheimer's patients easily shake off the medicine. The anti-falling medicine cup for dementia patients includes a cup body, the cup body includes a cup tube and a cup bottom, and also includes a movable cover and a fixed cover. The movable cover and the fixed cover include a movable cylinder and a fixed cylinder. Ring, a spring groove is formed between the fixed cylinder and the cup cylinder, the bottom end of the movable cylinder is embedded in the spring groove, and also includes a trumpet-shaped movable baffle sleeve and a fixed baffle sleeve, the open end of the movable baffle sleeve and the open large end of the fixed baffle sleeve are respectively It is connected with the top of the movable cylinder and the top of the fixed cylinder, the outer wall of the movable blocking sleeve is provided with a tooth-biting groove, a fixed plate is fixed on the small end of the opening of the fixed blocking sleeve, and the fixed blocking sleeve is provided with several medicine holes arranged near the small end of the fixed blocking sleeve. The spring groove is provided with a tension spring whose two ends are respectively connected with the bottom end of the movable cylinder and the fixing ring. This medicine cup can make the process of taking medicine safer.

The invention discloses an anti-dementia medicinal orally disintegrating tablet and a preparation method thereof, and relates to an anti-dementia medicinal orally disintegrating tablet and a prescription and a process for preparing the anti-dementia medicinal orally disintegrating tablet with a freeze-drying method. The anti-dementia medicinal orally disintegrating tablet disclosed by the invention is prepared from a main medicament and medicinal auxiliary materials, can be taken without water, is quickly disintegrated after being put into mouth, and is suitable for patients suffering from dysphagia such as the aged, children and the like; meanwhile, the anti-dementia medicinal orally disintegrating tablet is suitable for taking under the condition that a water source is difficult to obtain during traveling; the anti-dementia medicinal orally disintegrating tablet has the advantages of convenience for taking, quick absorption, small first pass effect, small irritation on digestive canal mucosa and the like, and has a wide market application prospect; and moreover, the anti-dementia medicinal orally disintegrating tablet can be used for remarkably reducing the side effects of an anti-dementia medicament. Moreover, the invention further relates to a preparation method of the anti-dementia medicinal orally disintegrating tablet.

The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.

The present invention relates to a percutaneous absorption preparation which can administer an anti-dementia drug stably and efficiently for a long period such as one week. More specifically, the present invention relates to a percutaneous absorption preparation comprising a drug-containing layer comprising an anti-dementia drug, a polymer compound having an amino group, a polyhydric alcohol fatty acid ester, a polyhydric alcohol, a polyvalent carboxylate ester, and a styrenic polymer compound.

The present invention relates to a percutaneous absorption preparation comprising an anti-dementia drug, which is lower skin irritation. More specifically, the present invention relates to a percutaneous absorption preparation comprising a drug-containing layer comprising an anti-dementia drug, a polymer compound having an amino group, a polyhydric alcohol fatty acid ester, a polyhydric alcohol, a polyvalent carboxylate ester, and a styrenic polymer compound, wherein the content of the anti-dementia drug is 0.5-20 mass % of the drug-containing layer.

The invention provides a method for detecting concentration of anti-dementia drugs in serum. The method has the advantages that the pretreatment operation is simple and rapid, the use amount of samples is small, the analysis time is short, and separation and detection of the three anti-dementia drugs in the serum can be completed within 4.5 min; matrix interference can be greatly eliminated by adopting an isotope internal standard method for quantification, the influence of conditions such as a pretreatment process, a sample loading volume and a flowing phase is avoided, and accurate quantification can be achieved; meanwhile, the clinical high-throughput sample detection requirements can be met, and a simple and rapid detection method is provided for concentration monitoring of clinical anti-dementia drugs.

Carambola roots belong to dry roots of oxalidaceae plant carambola trees. The inventor performs a large amount of long-term pharmacodynamic research on carambola roots. On the basis of the research, the research on a carambola root extract 2-dodecyl-6-methoxy-2,5-diene-1,4-cyclohexanedione (DMDD) finds that the carambola root extract has an obvious treatment effect on APP/PS1 dementia model mice.The invention may provide a new anti-dementia drug for senile dementia patients.

The invention discloses the application of polygala seedling extract in the preparation of anti-dementia medicine or health care product. The polygala seedling extract is obtained by the following preparation method: after drying and crushing of polygala seedling, 20%~ Ultrasonic extraction with 70% ethanol, extraction 1-2 times, 20-40 minutes each time, recovery of solvent, concentration under reduced pressure, vacuum drying to obtain Polygala seedling extract.

The invention relates to application of FTS (Trans Farnesyl Thiosalicylic Acid/Salirasib) in preparing an anti-dementia medicine. The application has the advantages that the cognitive disorder of an Alzheimer's Disease model mouse can be relieved by the FTS through oral or intraperitoneal injection, the toxicity of nerves and the withering of nerve cells of Abeta are reduced, and the synaptic transmission effect and long-time-course enhanced induction of a hippocampal brain area are restored; the synaptic transmission effect and long-time-course enhanced induction of the hippocampal brain area of the mouse are improved by the FTS through oral or intraperitoneal injection or cell incubation in a dose-dependent manner; the activity of a nerve cell glutamic acid NMDA receptor and the activity of an acetylcholine receptor alpha7 subtype can be enhanced by the FTS.